Overall, these data indicate that both glutamine and GART levels are increased in ERα-positive IDC, thus further suggesting that targeting the de novo purine biosynthetic pathway by reducing GART activity could be a valuable strategy to prevent ERα-positive BC progression. This evidence concerns the gene ESR1 and breast cancer.